✦ LIBER ✦

P-615 Phase II trials of gefitinib (‘Iressa’, ZD1839): rapid and durable objective responses in patients with advanced non-small-cell lung cancer (IDEAL 1 and IDEAl 2)

✍ Scribed by Fukuoka, Masahiro; Kris, Mark; Giaccone, Giuseppe; Lynch, Thomas; Nakagawa, Kazuhiko; Kelly, Karen; Wolf, Michael; McPartlane, Angela; Kay, Andrea; Fandi, Abderrahim

Book ID: 118572310
Publisher: Elsevier Science
Year: 2003
Tongue: English
Weight: 379 KB
Volume: 41
Category: Article
ISSN: 0169-5002
DOI: 10.1016/s0169-5002(03)92582-7

No coin nor oath required. For personal study only.

📜 SIMILAR VOLUMES

52 Rapid and durable objective responses

52 Rapid and durable objective responses in patients with advanced non-small-cell lung cancer in phase II trials (IDEAL 1 and IDEAL 2) treated with gefitinib

✍ U. Gatzemeier; J.Y. Douillard; M. Kris; M. Fukuoka; R. Herbst; J. Schiller; M. W 📂 Article 📅 2003 🏛 Elsevier Science 🌐 English ⚖ 170 KB

ZD1839 (‘Iressa’) provides clinically si

ZD1839 (‘Iressa’) provides clinically significant antitumor activity and improves disease-related symptoms in pretreated patients with advanced non-small-cell lung cancer (NSCLC): results of two Phase II trials (IDEAL 1 and IDEAL 2)

📂 Article 📅 2002 🏛 Elsevier Science 🌐 English ⚖ 277 KB

Activity of ZD1839 (Gefitinib, Iressa™)

Activity of ZD1839 (Gefitinib, Iressa™) in Previously Treated Patients with Recurrent and Advanced non—small-Cell Lung Cancer

✍ Angelia D. Gibson; Mark Socinski; Chandra P. Belani; Vinay K. Jain 📂 Article 📅 2002 🏛 CIG Media Group, LP. 🌐 English ⚖ 79 KB

O-242 Gefitinib (‘Iressa’, ZD1839) monot

O-242 Gefitinib (‘Iressa’, ZD1839) monotherapy for pretreated advanced non-small-cell lung cancer in IDEAL 1 and 2: tumor response is not clinically relevantly predictable from tumor EGFR membrane staining alone

✍ Bailey, Renee; Kris, Mark; Wolf, Michael; Kay, Andrea; Averbuch, Steven; Askaa, 📂 Article 📅 2003 🏛 Elsevier Science 🌐 English ⚖ 193 KB

P-228 Preliminary results of A phase II

P-228 Preliminary results of A phase II trial utilizing gemcitabine in patients with advanced non-small cell lung cancer and a performance status 2

✍ Joppert, Marcos; Marsland, Thomas; Whittaker, Thomas; Ahmad, Haroon; Neubauer, M 📂 Article 📅 2003 🏛 Elsevier Science 🌐 English ⚖ 187 KB

O-091 A randomized phase II trial of doc

O-091 A randomized phase II trial of docetaxel alone and in combinationwith gefitinib (IRESSA) as second-line therapy for patients with non-small-cell lung cancer

✍ Robinet, G.; Falchero, L.; Perol, M.; Thomas, P.; Monnet, I.; Grivaux, M.; Crequ 📂 Article 📅 2005 🏛 Elsevier Science 🌐 English ⚖ 140 KB